Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) Net Income towards Common Stockholders: 2020-2025

Historic Net Income towards Common Stockholders for Caribou Biosciences (CRBU) over the last 6 years, with Sep 2025 value amounting to -$29.4 million.

  • Caribou Biosciences' Net Income towards Common Stockholders rose 23.11% to -$29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.8 million, marking a year-over-year increase of 3.88%. This contributed to the annual value of -$149.1 million for FY2024, which is 46.08% down from last year.
  • As of Q3 2025, Caribou Biosciences' Net Income towards Common Stockholders stood at -$29.4 million, which was up 38.21% from -$47.6 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Net Income towards Common Stockholders ranged from a high of -$13.2 million in Q1 2021 and a low of -$47.6 million during Q2 2025.
  • For the 3-year period, Caribou Biosciences' Net Income towards Common Stockholders averaged around -$36.6 million, with its median value being -$38.2 million (2024).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 664.48% in 2021, then soared by 44.86% in 2023.
  • Over the past 5 years, Caribou Biosciences' Net Income towards Common Stockholders (Quarterly) stood at -$18.5 million in 2021, then crashed by 65.47% to -$30.6 million in 2022, then fell by 22.45% to -$37.4 million in 2023, then declined by 3.83% to -$38.9 million in 2024, then climbed by 23.11% to -$29.4 million in 2025.
  • Its Net Income towards Common Stockholders was -$29.4 million in Q3 2025, compared to -$47.6 million in Q2 2025 and -$42.9 million in Q1 2025.